Sanofi $SNY Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. boosted its holdings in Sanofi (NASDAQ:SNY) by 133.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,413,640 shares of the company’s stock after buying an additional 807,767 shares during the period. Victory Capital Management Inc. owned 0.06% of Sanofi worth $66,681,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Financial Consulate Inc. purchased a new stake in Sanofi during the third quarter valued at about $26,000. First Horizon Corp acquired a new stake in Sanofi during the 3rd quarter worth approximately $33,000. Salomon & Ludwin LLC raised its holdings in Sanofi by 1,046.3% in the third quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock valued at $39,000 after buying an additional 701 shares during the period. Nisa Investment Advisors LLC grew its stake in Sanofi by 233.3% during the second quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock worth $48,000 after buying an additional 700 shares during the period. Finally, Traub Capital Management LLC acquired a new stake in shares of Sanofi in the second quarter worth $51,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Price Performance

SNY stock opened at $45.00 on Friday. The stock’s 50 day moving average is $47.39 and its two-hundred day moving average is $48.51. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12. The company has a market capitalization of $109.76 billion, a PE ratio of 12.50, a P/E/G ratio of 1.20 and a beta of 0.45. The company has a quick ratio of 0.73, a current ratio of 1.09 and a debt-to-equity ratio of 0.20.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on SNY shares. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. UBS Group restated a “neutral” rating on shares of Sanofi in a research note on Friday, January 16th. Bank of America lowered Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. HSBC reissued a “buy” rating on shares of Sanofi in a research report on Wednesday, December 10th. Finally, Guggenheim downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. Five analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $62.67.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.